Gary Gilliland1, Jan Cools, Elizabeth H Stover, Iwona Wlodarska, Peter Marynen. Show Affiliations » 1. Brigham and Women's Hospital, Boston, MA, USA.
Abstract
Entities: Disease
Mesh： See more » AnimalsAntineoplastic Agents/therapeutic useBenzamidesCell Transformation, Neoplastic/geneticsEnzyme Inhibitors/therapeutic useHumansHypereosinophilic Syndrome/drug therapyHypereosinophilic Syndrome/enzymologyHypereosinophilic Syndrome/geneticsImatinib MesylateMastocytosis, Systemic/drug therapyMastocytosis, Systemic/enzymologyMastocytosis, Systemic/geneticsMiceOncogene Proteins, FusionOncogenesPiperazines/therapeutic usePyrimidines/therapeutic useRadiation ChimeraReceptor, Platelet-Derived Growth Factor alpha/antagonists & inhibitorsReceptor, Platelet-Derived Growth Factor alpha/geneticsReceptor, Platelet-Derived Growth Factor alpha/physiologyXenograft Model Antitumor AssaysmRNA Cleavage and Polyadenylation Factors/antagonists & inhibitorsmRNA Cleavage and Polyadenylation Factors/geneticsmRNA Cleavage and Polyadenylation Factors/physiology
Substances： See more » Antineoplastic AgentsBenzamidesEnzyme InhibitorsOncogene Proteins, FusionPiperazinesPyrimidinesmRNA Cleavage and Polyadenylation FactorsImatinib MesylateFIP1L1-PDGFRA fusion protein, humanReceptor, Platelet-Derived Growth Factor alpha
Year: 2004 PMID： 15190295 DOI： 10.1038/sj.thj.6200439
Source DB: PubMed Journal: Hematol J ISSN： 1466-4860